• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Pembrolizumab associated improved survival for NSCLC compared to platinum-based chemotherapy

byDavid ArsaniousandShaidah Deghan, MSc. MD
November 12, 2016
in Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Progression free survival and overall survival was significantly increased in patients who received pembrolizumab vs. patients who received platinum-based chemotherapy.

2. Treatment related toxicities were nearly doubled in the chemotherapy group vs. the pembrolizumab group.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Pembrolizumab is a humanized monoclonal antibody against programmed death ligand 1 (PD-L1). A substantial proportion of patients with advanced non-small-cell lung cancer (NSCLC) have high levels of membranous PD-L1 expression, and therefore multiple iterations of the KEYNOTE studies have sought to investigate the role of pembrolizumab in the primary treatment of NSCLC.

In this study, subjects with previously untreated NSCLC were randomly assigned to receive either pembrolizumab or platinum-based chemotherapy (most commonly carboplatin plus pemetrexed). The primary end point of the study was progression-free survival. Secondary endpoints included overall survival, objective response rates, and safety. There was a significant increase in the primary end point for the pembrolizumab group vs. the chemotherapy group. This was also demonstrated for the secondary outcomes of overall survival and objective response rate. The proportion of treatment associated toxicities was nearly double in the chemotherapy group. This study draws strength from its rigorous inclusion and exclusion criteria that included both clinical and molecular genetic characteristics.

Click to read the study, published today in NEJM

Relevant Reading: Pembrolizumab for the treatment of non–small-cell lung cancer

RELATED REPORTS

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

In-Depth [randomized controlled trial]: A total of 305 patients were randomly assigned in a 1:1 ratio to the pembrolizumab group (n = 154) or the chemotherapy group (n = 151). The median duration of follow-up was 11.2 months (range 6.4 to 19.7 months). The median time to reach the primary outcome, progression-free survival, for the pembrolizumab group was 10.3 months (95%CI 6.7 months to not reached) vs. 6.0 months (95%CI 4.2 to 6.2 months) in the chemotherapy group. For overall survival at 6 months, this was found to be 80.2% (95%CI 72.9 to 85.7%) in the pembrolizumab group and 72.4% (95%CI 64.5 to 78.9%) in the chemotherapy group (HR 0.60; 95%CI 0.41 to 0.89; p = 0.005). Objective response rate was 44.8% (95%CI 36.8 to 53.0%) in the pembrolizumab group and 27.8% (95%CI 20.8 to 35.7%) in the chemotherapy group. Grade 3, 4, or 5 adverse events occurred in 53.3% of the chemotherapy group and 26.6% of the pembrolizumab group.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chemotherapylung cancernon-small cell lung cancer
Previous Post

Nivolumab improves survival in head and neck squamous cell carcinoma: The CheckMate 141 trial

Next Post

Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

June 14, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Next Post
Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis

Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis

Decreased prevalence of HPV among vaccinated young females

Genotyping for HPV 16/18 may help guide colposcopy referrals for women with high risk HPV

Solitary kidney not associated with contrast-induced nephropathy

Ledipasvir-sofosbuvir may be safe treatment for kidney transplant recipients with chronic HCV

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
  • #VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.